PD-L1 antibody (Extracellular Domain)
Quick Overview for PD-L1 antibody (Extracellular Domain) (ABIN6990233)
Target
See all PD-L1 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- Extracellular Domain
-
Specificity
- PD-L1 Antibody has no cross-reactivity to PD-L2.
-
Purification
- PD-L1 Antibody is supplied as protein A purified IgG1.
-
Immunogen
- Anti-PD-L1 antibody was raised against the extracellular domain of human PD-L1.
-
Isotype
- IgG1
-
-
-
-
Application Notes
-
WB: 0.25 - 4 μ,g/mL, IF: 2 μ,g/mL, IHC-P: 5 μ,g/mL, ICC: 1 μ,g/mL.
Antibody validated: Western Blot in human and mouse samples, Immunohistochemistry, Immunocytochemistry and Immunofluorescence in human samples. All other applications and species not yet tested. -
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 1 mg/mL
-
Buffer
- PD-L1 Antibody is supplied in PBS containing 0.02 % sodium azide and 50 % glycerol.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C,4 °C
-
Storage Comment
- PD-L1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
-
-
- PD-L1 (CD274 (PD-L1))
-
Alternative Name
- PDL1
-
Background
- PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).
-
Molecular Weight
-
Predicted: 33kD
Observed: 37kD kDa -
Gene ID
- 29126
-
NCBI Accession
- NP_054862
-
UniProt
- Q9NZQ7
-
Pathways
- Cancer Immune Checkpoints
Target
-